GlaxoSmithKline's ($GSK) experimental malaria vaccine may not have delivered results as strong as the company hoped. But it does offer enough protection to slash the number of cases in infants for a time, a new study shows, and so Glaxo plans to ask European regulators for approval. The vaccine could be shipped by 2015. Report